Pelvic malignancies consistently pose significant global health challenges, adversely affecting the
well-being of the male population. It is anticipated that clinicians will continue to confront these cancers in their
practice. Nanomedicine offers promising strategies that revolutionize the treatment of male pelvic malignancies
by providing precise delivery methods that aim to improve the efficacy of therapeutic outcomes while minimizing
side effects. Nanoparticles are designed to encapsulate therapeutic agents and selectively target cancer
cells. They can also be loaded with theragnostic agents, enabling multifunctional capabilities.

Multiple databases, including PubMed, the National Library of Medicine, and Embase, were utilized to
locate and review recently published articles on advancements in nano-drug delivery for prostate and colorectal
cancers.

This review aims to summarize the latest nanomedicine research into clinical applications, focusing on
nanotechnology-based treatment strategies for male pelvic malignancies, encompassing chemotherapy, radiotherapy,
immunotherapy, and other cutting-edge therapies. The review is structured to assist physicians,
particularly those with limited knowledge of biochemistry and bioengineering, in comprehending the functionalities
and applications of nanomaterials.

Nanomedicine possesses considerable potential in improving therapeutic outcomes and reducing
adverse effects for male pelvic malignancies. Through precision delivery methods, this emerging field presents
innovative treatment modalities to address these challenging diseases. Nevertheless, the majority of current
studies are in the preclinical phase, with a lack of sufficient evidence to fully understand the precise mechanisms
of action, absence of comprehensive pharmacotoxicity profiles, and uncertainty surrounding long-term
consequences.